Is Pfizer Stock A Better Pick Over AbbVie?
Given its better valuation, we believe that Pfizer stock (NYSE: PFE) is currently a better pick than its industry peer – AbbVie stock (NYSE:ABBV). PFE stock trades at a much lower multiple of 11x ...
Spotlight on AbbVie: Analyzing the Surge in Options Activity
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with ...
Can AbbVie Regain Its Status As a Top Dividend Growth Stock?
Even more alarming is AbbVie's payout ratio of 216.7%, far surpassing the peer average of 141%. This sky-high figure means ...
AbbVie Inc. stock outperforms competitors despite losses on the day
AbbVie Inc. closed $6.48 below its 52-week high ($199.95), which the company reached on September 3rd.
Yahoo Finance5d
AbbVie (ABBV) Stock Dips While Market Gains: Key Facts
The latest trading session saw AbbVie (ABBV) ending at $193.45 ... changes in estimates have a direct relationship with upcoming stock price performance. To exploit this, we've formed the Zacks ...
AbbVie Inc. stock underperforms Tuesday when compared to competitors
The stock's fall snapped a two-day winning streak.
Yahoo Finance6d
Can AbbVie Regain Its Status As a Top Dividend Growth Stock?
AbbVie (NYSE: ABBV) has long been a darling of dividend growth investors, and for good reason. Since its spinoff from Abbott Laboratories in 2013, the pharmaceutical titan has been a dividend ...
Competitor Analysis: Evaluating AbbVie And Competitors In Biotechnology Industry
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013.
The Motley Fool6d
Can AbbVie Regain Its Status As a Top Dividend Growth Stock?
This conservative valuation indicates the market isn't fully sold on AbbVie's post-Humira growth strategy. The stock appears to be in "prove it" mode, with investors waiting to see how well the ...